TNYA Stock — Tenaya Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$0.69

Market cap

$156.47M

Price action

19 metrics

Price change (1W)

-2.3%

Price change (30D)

-6.0%

Price change (3M)

-13.2%

Price change (6M)

+24.6%

Price change (YTD)

-3.7%

Price change (1Y)

-39.3%

Trailing year

Price change (5Y)

-96.4%

52-week high

$2.10

52-week low

$0.55

Change from 52-week high

-67.4%

Change from 52-week low

+24.6%

Annualized volatility

102.1%

Beta

2.4

RSI (14D)

40.0

Price vs SMA 50

-9.7%

Price vs SMA 200

-15.1%

Avg volume (3M)

2.37M

Relative volume

0.5

Average dollar volume

$1.81M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

224.23M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

2.3

reciprocal yield 44.4%

FCF yield

-33.6%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-65.9%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-05-15

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$105.86M

Net income (TTM)

−$103.11M

Trailing 12 months

Diluted EPS (TTM)

$-0.50

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-67.19

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+33.7%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-148.6%

Return on assets

-110.2%

Debt / equity

—

Current ratio

4.5

EBITDA (TTM)

−$98.73M

Free cash flow (TTM)

−$52.59M

Quick ratio

4.5

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$78.08M

Total assets

$93.54M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$52.33M

Capital expenditures (TTM)

$263,000

R&D (TTM)

$61.61M

SG&A (TTM)

—

Stock compensation (TTM)

$9.58M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

101

13F filer change QoQ

-2

Institutional ownership

24.1%

Short interest

3 metrics

Short interest

9.4%

Latest settlement · 10.0 days to cover

Days to cover

10.0d

Short-squeeze score

68 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$21,048

Insider-sentiment score

44 / 100

Risk flags

1 metrics

Going concern

—

TNYA · Tenaya Therapeutics, Inc.

TNYA metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search